Biomarkers and Adjuvant Treatment Planning Strategies for Patients with a Node-Negative, Estrogen Receptor-Positive Breast Cancer
David M. Hyams, MD, FACS and Ruth Oratz, MD, FACP

Molecularly Targeted Therapies for Breast Cancer
Timothy J. Hobday, MD; Edith A. Perez, MD

Monoclonal Antibody Therapy for Breast Cancer
Edith A. Perez, MD - Mayo Clinic Cancer Center, Jacksonville, Florida

Medical Genomics: Implications for Clinical Oncology
Charles H. Weaver, MD, and Dayna Deuter

Small HER2-positive Breast Cancers Have a Higher Risk of Recurrence (11/6/2009)
Researchers from the M. D. Anderson Cancer Center and the University of Milan, Italy, have reported that women with Stage T1a,b, N0M0 HER2-positive breast cancers have a have a high recurrence rate without the administration of adjuvant chemotherapy or Herceptin® (trastuzumab). These data suggest that these women should be treated with Herceptin®-based adjuvant chemotherapy. The details of these two studies appeared in early online publications on November 2, 2009 in the Journal of Clinical Oncology.

Breast Self-examination Detects New Breast Cancers in High-risk Women (10/22/2009)
Researchers from Duke University have reported that breast self-examination (BSE) is a useful technique for detecting breast cancer in high-risk women. The details of this study were published in the October 2009 issue of the American Journal of Surgery.

Understanding Cancer Video Series Documents SABCS 2009 (10/20/2009)
CancerConsultants.com and Women Magazine have partnered to produce compelling and educational video coverage of The San Antonio Breast Cancer Symposium (SABCS) for the ongoing educational video series, Understanding Cancer.  The SABCS videos will be podcast and syndicated to cancer centers and clinics nationally as well as www.cancerconsultants.com.

Breast Tenderness After Hormone Replacement Therapy Associated with Increased Risk of Breast Cancer (10/20/2009)
Researchers affiliated with the Women’s Health Initiative Estrogen + Progesterone Trial have reported that breast tenderness occurring in postmenopausal women after taking hormone replacement therapy (HRT) is associated with an increased risk of developing breast cancer compared with women taking HRT who do not develop breast tenderness. The details of this study appeared in the October 12, 2009 issue of the Archives of Internal Medicine.

Vitamin D Deficiency Common in Breast Cancer (10/19/2009)
Researchers from the University of Rochester have reported that 69% of women with localized breast cancer receiving adjuvant therapy were deficient in vitamin D. Vitamin D deficiency was corrected with high-dose, as opposed to low-dose, vitamin D supplementation. The details of this study were presented at the American Society of Clinical Oncology breast cancer symposium on October 8, 2009 in San Francisco.